Onco?Innovations’ Stock Stalls as CMC Advance Fails to Spark Investor Enthusiasm

Shares fall 2% to €0.49 as biotech advances manufacturing for experimental cancer drug, but lack of clinical catalysts keeps stock in downtrend; RSI near oversold at 33.

Onco?Innovations has taken a necessary but unglamorous step in bringing its experimental cancer drug ONC010 closer to the clinic, yet the market is giving the company little credit for the move. Shares slipped 2% to €0.49 on Wednesday, bringing the year?to?date decline to roughly 44%. The stock now trades more than two?thirds below the 52?week high of €1.49 set last July, and the RSI sits at 33 — technically near oversold territory but hardly enough to attract bargain hunters on its own.

The biotech said it has launched a new chemistry, manufacturing and controls (CMC) workstream for A83B4C63, the active pharmaceutical ingredient that underpins ONC010. Working with contract development and manufacturing organisation Dalton Pharma Services, the company aims to optimise synthetic routes, improve yield and reproducibility, and scale up the production of intermediates. CEO Thomas O’Shaughnessy described the effort as part of “translating scientific work into a clinically usable product,” emphasising that a scalable, reproducible manufacturing process is fundamental to the company’s development strategy.

Yet for investors the update is purely operational. The company did not release any fresh clinical efficacy data, nor did it provide a timeline for the start of human studies. The analytical validation of the process remains outstanding, and Onco?Innovations has yet to complete the IND?enabling studies it has linked to the workstream. Until those concrete regulatory filings materialise, the stock lacks a fundamental catalyst strong enough to reverse the entrenched downtrend.

Technically, the picture remains bleak. The shares are well below the short?term moving average of €0.60, and the gap from the 52?week peak of €1.49 now sits at roughly 67%. Even the modest intraday bounce toward €0.50 did little to alter the trajectory — the daily change was effectively flat for those who bought earlier, while sellers continued to dominate the session. The single bright spot is the RSI reading, which at 33 signals that the stock may be approaching a bottom, but such a metric offers no guarantee of an imminent rebound unless backed by a genuine news event.

Manufacturing infrastructure is a necessary building block for any drug developer, but it is far from sufficient to support a valuation. Onco?Innovations now needs to translate this production progress into something investors can clearly measure: an IND submission, a phase 1 start date, or, eventually, clinical data. Until then, ONC010 remains a development promise — and the stock is being priced accordingly.